Evidence map›Paper›PMID 41037768›Full record

ArticleJCO oncology practice2026

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

Christopher Strouse, Mark Juckett, Brent R Logan, Noel Estrada-Merly, Andrew Peterson, Jaime M Preussler, Tony H Truong, Jesse D Troy, Nandita Khera, William A Wood and 6 more

Abstract read
In one paragraph

Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christopher StrouseDivision of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA.ORCID 0000-0003-4964-167X
Mark JuckettDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
Brent R LoganDivision of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-4473-4044
Noel Estrada-MerlyCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0009-0008-4479-8882
Andrew PetersonCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Jaime M PreusslerNational Marrow Donor Program/Be The Match, Minneapolis, MN.ORCID 0000-0001-7047-5720
Tony H TruongDivision of Pediatric Oncology, Blood and Marrow Transplant, Alberta Children's Hospital, Calgary, AB, Canada.ORCID 0000-0002-0991-7961
Jesse D TroyDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.ORCID 0000-0002-0577-3155
William A WoodDivision of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC.ORCID 0000-0001-7439-2543
Hemalatha G RangarajanDepartment of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH.
Luke P AkardIndiana Blood and Marrow Transplantation, Franciscan Health, Indianapolis, IN.
Neel S BhattDepartment of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplant, University of Washington School of Medicine, Seattle, WA.ORCID 0000-0003-2033-1125
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3281-2081
J Douglas RizzoCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0003-1474-1152
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-6544-5815

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosageU01AI184132 · NIAID · NATIONAL MARROW DONOR PROGRAM · PI JEFFERY J AULETTA, Michael A Pulsipher · 2024 to 2026
$3.2M
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening DiseasesUG1HL174426 · NHLBI · NATIONAL MARROW DONOR PROGRAM · PI Leslie S Kean, Heather E Stefanski · 2024 to 2026
$513k
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500k
NCI NIH HHS U24 CA076518NHLBI NIH HHS UG1 HL174426NIAID NIH HHS U01 AI184132NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
6 · The paper itself

Abstract

purposePublic reporting of health care outcomes can have unintended effects such as inappropriate risk aversion in patient selection.

methodsThe center-specific survival analysis annually assigns all hematopoietic cell transplantation (HCT) centers in the United States a +1, -1, or 0 score for observed outcomes that are above, below, or within a center-specific predicted range of outcome. For each index year (2012-2016), centers receiving a -1 score after 0 scores in the preceding 2 years were compared with contemporaneous centers with as-predicted outcomes (0 score). Changes in the patient population characteristics in the 3 years before versus the 3 years after the index years were compared between the newly below-expected centers (NBCs) and the controls. A multivariate model adjusted for baseline patient population characteristics and center volume.

resultsNo differences in patient selection behavior were identified when comparing the NBCs with the controls across eight key patient population characteristics. For the statistically modeled (predicted) 1-year overall survival (OS), reflecting a holistic measure of centers' patient population risk, we observed no statistically significant difference in change (-0.23% [95% CI, -1.4 to 0.9];

conclusionCenters receiving a -1 score were not observed to deviate significantly from patient selection trends in the HCT field. These findings suggest that public reporting of HCT outcomes in the United States does not result in unintended bias against HCT for high-risk patients.

Indexed as

Hematopoietic Stem Cell TransplantationOutcome Assessment, Health CarePatient SelectionAdultFemaleHumansMaleMiddle AgedUnited States

Identifiers

PMID41037768
PMCPMC12494149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.